Autoimmune diseases, immune modulation, inflammation, and self-tolerance
200 articles
A multi-biomarker study finds pwMS show accelerated thymic involution, senescent T cell expansion, and neuroinflammation linked to aging.
A comparative protein interaction map of SARS-CoV-2 and its bat progenitor uncovers the molecular switch behind immune evasion and species barriers.
A newly identified immune axis involving CD16+ γδ T cells and antibody-dependent killing may reshape how we understand HBV immune control.
A runaway immune response — not the pathogen itself — drives citrus greening disease, echoing autoimmune mechanisms seen in human illness.
A novel biologic targeting IL-33 shows promising advances in COPD treatment, potentially reshaping how chronic lung disease is managed.
A murine arthritis study finds rapamycin suppresses neuropeptide Y, linking cellular senescence to joint inflammation via SASP cytokines.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
JAMA publishes a timely review of IgA nephropathy, the leading cause of primary glomerulonephritis worldwide, amid a wave of new therapies.
Nephrologists from Canada and Ireland address clinical questions on IgA nephropathy, one of the most common causes of kidney failure worldwide.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
Go beyond inflammaging basics to understand how aging reshapes immune cell populations, triggers the SASP, and locks the body into a state of chronic low-grade inflammation at the molecular level.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
